Proof of Concept Study With an Endothelin Receptor B Inhibitor (BQ-788) for Human Melanoma
Intra-lesion administration of an Endothelin Receptor B inhibitor (BQ-788) or vehicle was preformed in 5 melanoma patients to have a preliminary analysis of safety, dose, duration and relevance of results observed in pre-clinical studies to the human disease.
100 项与 Melcure SA (Switzerland) 相关的临床结果
0 项与 Melcure SA (Switzerland) 相关的专利(医药)
100 项与 Melcure SA (Switzerland) 相关的药物交易
100 项与 Melcure SA (Switzerland) 相关的转化医学